11/5/2026

speaker
Conference Operator
Operator

Good morning and welcome to the Vietris Q3 2026 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touch-tone phones. To withdraw your questions, you may press star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Bill Szablewski, Head of Capital Markets. Please go ahead.

speaker
Bill Szablewski
Head of Capital Markets

Good morning, everyone. Welcome to our Q3 2026 earnings call. With us today is our CEO, Scott Smith, Interim CFO, Paul Campbell, Chief R&D Officer, Philippe Martin, and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risk and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information. including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures. When discussing 2026 actual or reported results, we will be making certain comparisons to 2025 actual or reported results on an operational basis, which excludes the impact of foreign currency rates. When comparing our 2026 actual reported results to our expectations, We are making comparisons to our 2026 financial guidance. With that, I'll hand the call over to our CEO, Scott Smith.

speaker
Scott Smith
Chief Executive Officer

Good morning, everyone. We're pleased with our strong third quarter performance, which reflects continued momentum across our businesses. As we've been saying, we believe we've entered a new phase of sustained growth for Beatrice. The disciplined execution of the strategy we outlined earlier this year is translating into results. During the third quarter, we delivered total revenues of $3.75 billion, adjusted EBITDA of $1.2 billion, and adjusted EPS of 71 cents per share. Through the first nine months of the year, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally compared to the prior year, demonstrating continued progress towards our long-term financial targets. Given our performance and expectations for continued momentum in the fourth quarter, we are narrowing our financial guidance ranges and once again raising the midpoint for all key financial metrics. Paul will provide more details shortly. Now let me walk through a few highlights for the quarter. Our base business continues to deliver solid results reflecting the strength and durability of our portfolio. We're pleased with our performance in North America and greater China, where we continue to see meaningful growth. In North America, growth is accelerating as our portfolio mix shifts towards more durable, higher-margin products and complex generics, supported by strong demand for our estradiol patches and new product revenue from our recent injectable launches. We are pleased to have launched Winlow, our low-dose contraceptive patch, in the US in October. In Greater China, growth continues to be driven by strong demand for our cardiovascular portfolio and the strength of our established brands. Regarding our pipeline, we continue to make meaningful progress in advancing our innovative medicines portfolio and positioning the business for long-term growth. In Japan, we received regulatory approval for Wakex, which we expect to be an important product launch and a key contributor to the country's strategy to return to growth. In the U.S., we received approval for ResumeV for the treatment of presbyopia. and we continue to advance our preparations for the potential approval and launch of Fast-Acting Meloxicam. As a reminder, the PDUFA date for Fast-Acting Meloxicam is December 27th and if approved, we expect to launch early in 2027. In addition, we are approaching the phase three readouts for Slatagrel and Sneramod representing significant milestones for Innovative Medicine's portfolio. Both products have blockbuster potential and could become important growth drivers for us in the next decade. Philippe will provide additional details on these programs and the pipeline shortly. Finally, I'd like to take a moment to discuss our recently announced agreement to acquire Pacera Biosciences and the strategic opportunities we believe this transaction will create for Beatrice. I'm excited about the potential of the Pacera business. I believe this acquisition represents a significant step forward for Beatrice and is a strong example of the business development strategy we are executing to support our long-term growth. More specifically, the transaction would add two established patent-protected medicines in the U.S., Expirel and Zolretta, further strengthening our U.S. promoter brands business with durable revenue and margins well above our company average. With the addition of Paceris products, we expect our U.S. innovative medicines business to generate more than a billion dollars in total revenue in 2027. We're also exploring potential opportunities to leverage our global infrastructure to develop and commercialize Pacera's products in selected markets outside of the U.S. Additionally, Pacera would bring an experienced U.S. team and established capabilities across sales, marketing, market access, medical affairs, and global R&D that complement our existing infrastructure. We believe these capabilities could help us maximize The potential of Fast Acting Block Scam and position Beatrice to become a leader in non-opioid pain management. Before I turn it over to Philippe, I want to recognize a recent leadership transition. After more than 30 years with Beatrice and our legacy companies, Peter McCormick retired as our Chief Supply Officer on November 1st. I want to personally thank Peter for his tremendous contribution and years of dedicated leadership. With Peter's transition, I'm very pleased to welcome Paul Duffy as our new Chief Supply Officer. Paul brings 35 years of industry experience across global supply chain management, manufacturing, strategy, and business transformation. I'm looking forward to working very closely with him. With that, I'll turn it over to Philippe. Philippe?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation